Fibrate drugs (e.g., peroxisome proliferator-activated receptor α [PPAR α] agonists), nicotinic acid derivatives, and eicosapentaenoic acid preparations have been used to treat dyslipidemia patients with high TG levels and low HDL-C levels [5]. Here, PPARA is linked to metabolic syndrome.